VACCIBODY ANNOUNCES COLLABORATION TO STUDY VB10.16 AND ATEZOLIZUMAB (TECENTRIQ®) IN ADVANCED CERVICAL CANCER

On February 13, 2019 Vaccibody AS, a clinical stage immuno-oncology company, reported that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq) in patients with advanced cervical cancer (Press release, Vaccibody, FEB 13, 2019, View Source [SID1234533281]). Vaccibody expects to start a phase II study with up to 50 patients in the second half of 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Martin Bonde, CEO of Vaccibody, said: "We are very pleased with this collaboration. This is an important study as it explores a novel targeted treatment approach that addresses the high medical need of patients with advanced cervical cancer." Agnete Fredriksen, President and CSO of Vaccibody added: "The combination of VB10.16 and atezolizumab is building on the positive data VB10.16 has generated as monotherapy in patients with precancerous cervical lesions. In this study, it was observed that VB10.16 creates a target for PD-1/PD-L1 checkpoint inhibitors, thereby providing a sound scientific rationale for combining VB10.16 with an immune-checkpoint inhibitor like atezolizumab in cervical cancer patients."

The planned study will assess the safety, tolerability, immunogenicity and efficacy of the VB10.16-atezolizumab combination in patients with advanced cervical cancer.

About VB10.16

VB10.16 is an investigational therapeutic DNA vaccine developed to treat human papillomavirus type 16 (HPV16) induced pre-malignancies and malignancies. The drug candidate has demonstrated favorable 6M interim clinical data in a Phase I/IIa study in pre-cancerous HPV16 induced high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

About cervical cancer

Cervical cancer is the most commonly occurring cancer among women in developing countries and is the second most commonly occurring cancer amongst women worldwide. An estimated 45,800 cases of cervical cancer will be diagnosed in the US and EU in 2019 and similarly an estimated 18,400 deaths from cervical cancer will occur in 2019. Cervical cancer is caused by high risk HPV. HPV16 is the type that most frequently causes cancer. It has been reported to be the most common genotype in high grade cervical intraepithelial neoplasia. It is detected in up to 60% of all cervical cancers, especially in younger women and it has also been found to play an essential role in the development of several other cancer types (approximately 90% of anal cancers; 40% of penile, vaginal, and vulvar cancers; 25% of oral cavity cancers and 35% of oropharyngeal cancers). Gardasil and Cervarix are preventive HPV vaccines which prevent infection of HPV, but these do not have an effect in already infected patients. A high percentage of the eligible population for the preventive vaccines does not get vaccinated, thus HPV infection and HPV+ cancer still requires effective therapeutic interventions. There is currently no available therapy treating HPV specifically.

BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong

On February 13, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will hold a fourth quarter and full year 2018 financial results conference call and webcast on Wednesday, February 27, 2019, at 6:00 p.m. ET (Press release, BeiGene, FEB 13, 2019, View Sourcephoenix.zhtml?c=254246&" target="_blank" title="View Sourcephoenix.zhtml?c=254246&" rel="nofollow">View Source;p=RssLanding&cat=news&id=2387405 [SID1234533301]). On the call, Company management will provide an overview of BeiGene’s financial results for the fourth quarter and full year 2018, and updates on recent business highlights and upcoming milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BeiGene will also host an in-person and webcast investor event in Hong Kong on Thursday, February 28, at 2:30 – 4:00 p.m. HKT (Thursday, February 28, at 1:30 – 3:00 a.m. ET) at the Island Shangri-La Hong Kong.

Financial Results Conference Call and Webcast Information
Investors and analysts are invited to join the conference call using the following dial-in information:
U.S. Toll-Free: (844) 461-9930
Hong Kong: 3011-4522
China: 400-682-8609
Conference ID: 8889396

A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available two hours after the event for 90 days.

Hong Kong Investor Event, Conference Call and Webcast Information
Hong Kong Investor Event
Date and Time: Thursday, February 28, at 2:30 p.m. HKT (Thursday, February 28, at 1:30 a.m. ET)
Location: Island Shangri-La, Hong Kong, Level 5, Ballroom A

A live webcast of the investor event can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available two hours after the event for 90 days.

Cartherics Pty Ltd teams up with Canada’s panCELLa Inc to bring the power of safe cell therapy to a greater number of patients

On February 13, 2019 Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy (Press release, Cartherics, FEB 13, 2019, View Source [SID1234553814]). panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary homozygous HLA haplotype cells to bring the power of safe cell therapy to a greater number of patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This technology is an important step to ensure the safety of the next generation of very effective gene-edited stem cell-derived immunotherapies," said Prof. Alan Trounson, CEO Cartherics.

Leveraging the science recently published in "Linking a cell division and a suicide gene to define and improve cell therapy safety" in the November 21st 2018 issue of Nature, panCELLa will maximize the safety level of Cartherics unique therapeutic cancer-killing cells (CAR-T Cells) by building in a molecular kill-switch among the genes of the cells, enabling the efficient elimination of dangerously dividing or rogue cells.

"We anticipate that this partnership will provide for the highest level of cell therapy safety," stated Dr. Andras Nagy, President and CSO of panCELLa. "We are pleased to partner with Cartherics to address the needs of immunotherapy treated cancer patients and to generate a FailSafe cell source for cell therapies in regenerative medicine. It is our mission to provide off-the-shelf universally safe cell therapies for all humankind."

Doer Biologics Received tens of millions RMB in its first financing

On February 13, 2019 Doer Biologics reported in January 2019, Doer Biologics has closed tens of millions RMB in its first financing (Press release, Doer Biologics, FEB 13, 2019, View Source [SID1234656201]). The Series A round was led by Kaitai Capital, with participation from Hangzhou Bairui Investment Company. Doer Biologics devotes to the development of multi-domain innovative biopharmaceutics, focusing on unmet clinical needs. Based on its MultipleBody and XLong long acting technology platforms, Doer biologics has developed DR10619, DR30121 and other products, which are significantly competitive in the field of NASH and AMD. Its first financing will certainly facilitate the progress of its products to IND application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019

On February 13, 2019 Genomic Health, Inc. (NASDAQ: GHDX) reported that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results (Press release, Genomic Health, FEB 13, 2019, View Source [SID1234533285]). The call and webcast will follow the release of the fourth quarter and year-end financial results after market close.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details

To access the live conference call on February 20 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada, or +1 (224) 357-2389 internationally. The conference call ID is 8989205. Please dial in approximately ten minutes prior to the start of the call.

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s web site at View Source Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary.